Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study demonstrates substantial immune response in individuals infected with SARS-CoV-2 Omicron variant

by Medical Finance
in Coronavirus
Study: Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. Image Credit: Gurudev / Shutterstock.com
11
SHARES
126
VIEWS
Share on FacebookShare on Twitter

The recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) has led to a new wave of coronavirus disease 2019 (COVID-19) cases globally. The increased virulence of the Omicron variant has allowed for this new strain of SARS-CoV-2 to displace the previously dominant Delta variant throughout most countries in the world.

Study: Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. Image Credit: Gurudev / Shutterstock.com

Study: Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern. Image Credit: Gurudev / Shutterstock.com

The third COVID-19 wave imposed by the Omicron VOC impacted India in January 2022. The Omicron variant has higher transmissibility and immune escape capabilities that have been implicated in its rapid spread and numerous breakthrough and re-infections.

However, the resultant disease following infections with this variant appears to be less severe compared to that with other VOCs. It is therefore important to ascertain the potential for immune evasion of the Omicron variant among vaccinated individuals and those who have had natural infection.

About the study

A recent study published on the bioRxiv* preprint server analyzed the immunoglobulin G (IgG) and neutralizing antibodies (NAbs) against the SARS-CoV-2 B.1, Alpha, Beta, Delta, and Omicron strains with the sera of individuals infected with the Omicron variant (B.1.1529 and BA.1).

Twenty-eight of the 39 participants selected for the current study were foreign returnees, whereas the remaining 11 were their high-risk contacts confirmed to be infected with the Omicron variant by next-generation sequencing (NGS). Sera samples were collected from all participants at about 10 days after the onset of symptoms. Oro/nasopharyngeal swabs of eight individuals were positive for SARS-CoV-2.

The study participants were categorized based on the vaccines they received. Group 1 included 25 individuals who received the ChAdOx1 nCoV-19 vaccine and experienced a breakthrough infection at an average of 147 after receiving their second dose.

Group 2 consisted of eight individuals who received the Pfizer-BioNTech BNT162b2 messenger ribonucleic acid (mRNA) vaccine and experienced a breakthrough infection at an average of 113 after their second dose. Group 3 included six unvaccinated individuals.

Study findings

The mean age of the participants in Group 1 was 39 years. Among these, 13 were asymptomatic, while twelve reported having mild fever, sore throat, and cough lasting for one to three days. Of these, two cases were of reinfection, with the last SARS-CoV-2 infection documented in July 2020.

The mean age of the participants in Group 2 was 33 years. Among these, only one participant had mild fever and sore throat, while the remaining were asymptomatic.

Meanwhile, the unvaccinated group consisted of only female participants of a mean age of 16 years. Five of the participants in this group were pediatric patients. In this group, four patients were asymptomatic, whereas two pediatric patients were mildly symptomatic.

The results of the current study showed that the geometric mean titers (GMTs) of the S1-receptor-binding domain (RBD) IgG antibodies in the sera of the Group 1 and Group 2 individuals were similar. However, nucleocapsid (N) protein GMTs were 2.5-3.6 times reduced in the sera of Group 2 individuals as compared to those of Group 1.

Group 3 showed varied responses in the GMTs of S1-RBD IgG antibodies.

Group 2 individuals also exhibited significant reductions in their GMTs against the Delta and Omicron variants at 1.52- and 7.41-fold, respectively. Notably, the participants in this group did not have a significant reduction in their GMTs against the Alpha and Beta variants.

IgG antibody response in breakthrough and unvaccinated individuals was assessed using ELISA.

IgG antibody response in breakthrough and unvaccinated individuals was assessed using ELISA.

Implications

Taken together, the researchers observed a three-fold reduction in NAb titers in BNT162b-vaccinated breakthrough infections when compared to ChAdOx1 nCoV-19 breakthrough infections. Furthermore, the researchers found that individuals infected with the SARS-CoV-2 Omicron variant harbor a significant immune response against most other SARS-CoV-2 VOCs, including the Delta variant.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinology. Image Credit: Design_Cells/Shutterstock

Study investigates incident diabetes burden and risk in post-acute COVID-19 patients

by Medical Finance
May 19, 2022
0

In a recent study published in The Lancet Diabetes and Endocrinology, researchers examined the post-acute risk and burden of incident...

Study: SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Image Credit: CROCOTHERY/Shutterstock

Clinical outcomes of SARS-CoV-2 coinfection with influenza viruses, respiratory syncytial virus, or adenoviruses

by Medical Finance
May 20, 2022
0

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has caused hundreds of millions of documented cases...

Study: Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. Image Credit: creativeneko/Shutterstock

Effectiveness of prior infection in preventing reinfection with Omicron and other SARS-CoV-2 variants in Qatar

by Medical Finance
May 19, 2022
0

In a recent study published on the medRxiv* preprint server, researchers estimate the effectiveness of prior infection in preventing reinfection (PEs)...

Study: Genetic and Immunological Characterization of Commercial Infectious Bronchitis Virus (IBV) Vaccines Used in Korea. Image Credit: Rawpixel.com/Shutterstock

Researchers characterize vaccines for infectious bronchitis virus

by Medical Finance
May 19, 2022
0

A recent study posted to the Research Square* server characterized the genetic and immunological aspects of the infectious bronchitis virus...

Study: Circadian misalignment is associated with Covid-19 infection. Image Credit: Troyan/Shutterstock

The relationship between circadian misalignment and the risk of COVID-19 infection

by Medical Finance
May 20, 2022
0

An interesting new study links changes in the daily rhythms of the human body with the risk of coronavirus disease...

Study: Adherence of SARS-CoV-2 delta variant to surgical mask and N95 respirators. Image Credit: Maridav/Shutterstock

Efficacy of surgical masks and N95 respirators in lowering SARS-CoV-2 transmission

by Medical Finance
May 19, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers determined the adherence of severe acute respiratory syndrome coronavirus 2...

Next Post
Study: New intranasal and injectable gene therapy for healthy life extension. Image Credit: nobeastsofierce / Shutterstock

Mice live longer with nasal gene therapy

The neutralizing mechanism of SARS-CoV-2 RBD neutralizing antibody.

Developing reagents for SARS-CoV-2 neutralizing antibody detection

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Herpesvirus Reactivations in Critically-Ill COVID-19 Patients with Autoantibodies Neutralizing Type I Interferons. Image Credit: Hananeko_Studio/Shutterstock
    Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients
  • Study: SARS-CoV-2 and human retroelements: a case for molecular mimicry? Image Credit: ThSucho/Shutterstock
    Similarities between SARS-CoV-2 and human retroelements explored
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply